Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Thomas Olencki"'
Autor:
David F. McDermott, Thomas Olencki, Ulka N. Vaishampayan, Mariajose Lechuga, Saby George, Kathrine C. Fernandez, Jamal Tarazi, Daniel C. Cho, Brad Rosbrook, Igor Puzanov, Toni K. Choueiri, Elizabeth R. Plimack, Mayer Fishman, Michael B. Atkins
Publikováno v:
The Lancet Oncology. 19:405-415
Summary Background Previous studies combining PD-1 checkpoint inhibitors with tyrosine kinase inhibitors of the VEGF pathway have been characterised by excess toxicity, precluding further development. We hypothesised that axitinib, a more selective V
Autor:
Jia You, Tracey Papenfuss, Taylor R. Brooks, Michael A. Freitas, Andrew Stiff, Isaac P. Foote, Joseph Markowitz, Zach Vangundy, Brandon J. Biesiadecki, Owen E. Branson, Thomas Olencki, Vedat O. Yildiz, Mitch A. Phelps, William E. Carson, Jiang Wang, Susheela Tridandapani, Lianbo Yu
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
Scientific Reports
Scientific Reports
Myeloid derived suppressor cells (MDSC) produce nitric oxide (NO) and inhibit dendritic cell (DC) immune responses in cancer. DCs present cancer cell antigens to CD4+ T cells through Jak-STAT signal transduction. In this study, NO donors (SNAP and DE
Autor:
Evan J. Lipson, Ragini R. Kudchadkar, Sunil Reddy, Tomoko Akaike, Thomas Olencki, William H. Sharfman, Philip Friedlander, Steven P. Fling, Mizuho Kalabis, Candice D. Church, Kari Kendra, Michi M. Shinohara, Adil Daud, Adam I. Riker, Harriet M. Kluger, Elad Sharon, Melissa Amber Burgess, Janis M. Taube, Paul Nghiem, Brent A. Hanks, Suzanne L. Topalian, Blanca Homet Moreno, Andrew S. Brohl, Brian C. Boulmay, Martin A. Cheever, Bob Salim, Erin Jensen, Shailender Bhatia, Nirasha Ramchurren
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Journal for immunotherapy of cancer, vol 9, iss 4
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 4
Journal for Immunotherapy of Cancer
BackgroundMerkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of durable tumor regression compared with chemotherapy for MCC. The current stud
Autor:
Darren R. Feldman, Toni K. Choueiri, Joel Picus, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson, Shaker R. Dakhil, Daniel J. George, Meghara K. Walsh, Thomas Olencki, Eric J. Small, Susan Halabi, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 35:591-597
Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma (mRCC). This randomized phase II multicenter trial evaluated cab
Autor:
Karina Furlan, Stephen Y. Kang, Amanda E. Toland, O. Hans Iwenofu, Theodoros N. Teknos, Ayse Selen Yilmaz, Priyadharsini Nagarajan, Thomas Olencki, Dawn C. Allain, Sara B. Peters, Hatice Gulcin Ozer, Jessica L. Gillespie, Leticia T. F. Castro, Madison N. Bernhardt
Publikováno v:
Cancer. 123:1184-1193
BACKGROUND Exome and targeted sequencing studies have identified potential driver mutations for a variety of tumor types. Cutaneous squamous cell carcinoma (cSCC) is one of the most highly mutated cancers but typically is associated with low rates of
Autor:
Sumanta K. Pal, Yousef Zakharia, Christopher W. Ryan, Judit Kocsis, Bruce G. Redman, Thomas Olencki, L. Robertson, Bonne J. Adams, Primo N. Lara, B.E. Simpson, Lajos Géczi, Alexandr Poprach, Neeraj Agarwal, Charles P. Theuer, M. Darif, Mollie deShazo, Toni K. Choueiri, Thai H. Ho, Russell K. Pachynski, László Mangel
Publikováno v:
Annals of Oncology. 30:v362-v363
Background Endoglin is an essential angiogenic receptor expressed on proliferating tumor vessels and RCC stem cells that is implicated as a mechanism of VEGF resistance. TRC105 is an endoglin monoclonal antibody that potentiates the anti-tumor activi
Autor:
Kimberly D Allman, Amir Mortazavi, Nancy B. Davis, Moshe Chaim Ornstein, Jorge A. Garcia, Brian P. Hobbs, Brian I. Rini, Timothy D. Gilligan, W. Kimryn Rathmell, Laura S. Wood, Xuefei S Jia, Sumanta K. Pal, Allison Martin, Thomas Olencki, Jackie M Tomer
Publikováno v:
The Lancet. Oncology. 20(10)
Summary Background Checkpoint inhibitor therapy is a standard of care for patients with metastatic renal cell carcinoma. Treatment options after checkpoint inhibitor therapy include vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase
Autor:
Martin A. Cheever, Steven P. Fling, Blanca Homet Moreno, Nirasha Ramchurren, Andrew S. Brohl, Thomas Olencki, Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Kim Margolin, Lisa Lundgren, Brian C. Boulmay, Harriet M. Kluger, Candice D. Church, Melissa Amber Burgess, Michi M. Shinohara, Suzanne L. Topalian, Bob Salim, Song Youn Park, Janis M. Taube, Paul Nghiem, Sunil Reddy, Nageatte Ibrahim, Steven R. Bird, Ragini R. Kudchadkar, Adam I. Riker, Abha Soni, Brent A. Hanks, Elad Sharon, Adil Daud, Phillip A. Friedlander
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 37, iss 9
PURPOSE Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for advanced MCC (aMCC) demonstrate increased progression-free survival (PFS)
Autor:
Xueliang Pan, Gregory B. Lesinski, Jeffrey Schlom, Renee N. Donahue, Thomas Olencki, Jacob Richards, Taylor R. Brooks, Volodymyr Karpa, Bonnie Paul, William E. Carson, Caroline Jochems, Megan C. Duggan, Elizabeth Foust, Susheela Tridandapani
Publikováno v:
Cancer Immunology, Immunotherapy. 65:1353-1364
Prime-boost vaccination with recombinant (r) vaccinia(V)-CEA(6D)-TRICOM (triad of co-stimulatory molecules B7.1, ICAM-1 and LFA-3) and rFowlpox(F)-CEA(6D)-TRICOM infect antigen-presenting cells and direct expression of co-stimulatory molecules. We hy
Autor:
Lianbo Yu, Andrew Stiff, Michael A. Freitas, Zach Vangundy, Vedat O. Yildiz, Mitch A. Phelps, Taylor R. Brooks, Jiang Wang, Joseph Markowitz, Jia You, Tracey Papenfuss, Thomas Olencki, William E. Carson, Brandon J. Biesiadecki, Isaac P. Foote, Susheela Tridandapani, Owen E. Branson
Publikováno v:
Scientific Reports
Scientific Reports, Vol 8, Iss 1, Pp 1-1 (2018)
Scientific Reports, Vol 8, Iss 1, Pp 1-1 (2018)
Myeloid derived suppressor cells (MDSC) produce nitric oxide (NO) and inhibit dendritic cell (DC) immune responses in cancer. DCs present cancer cell antigens to CD4